✦ LIBER ✦

Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis

✍ Scribed by Rognoni, Carla; Marchetti, Monia; Quaglini, Silvana; Liberato, Nicola Lucio

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness Analysis of Apixaban

✍ Canal Fontcuberta, C.; Escolar Albaladejo, G.; Betegón Nicolás, L.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Economic Evaluation of Warfarin, Dabigat

✍ Wisløff, Torbjørn; Hagen, Gunhild; Klemp, Marianne 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 765 KB

Cost-Effectiveness Analysis of Apixaban

✍ Betegón Nicolás, L.; Escolar Albaladejo, G.; Canal Fontcuberta, C.; de Salas-Can 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Lifetime costs and life-years gained ass

✍ Harrington, A.R.; Armstrong, E.P.; Nolan, P.; Malone, D.C. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Cost-effectiveness of Dabigatran for Str

✍ González-Juanatey, José R.; Álvarez-Sabin, José; Lobos, José M.; Martínez-Rubio, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 355 KB

Cost-effectiveness of apixaban vs warfar

✍ Kamel, H.; Easton, J. D.; Johnston, S. C.; Kim, A. S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 578 KB